PURPOSE: Data suggest that circulating 25-hydroxyvitamin D [25(OH)D] interacts with the vitamin D receptor (VDR) to decrease proliferation and increase apoptosis for some malignancies, although evidence for prostate cancer is less clear. How VDR expression in tumor tissue may influence prostate cancer progression has not been evaluated in large studies. PATIENTS AND METHODS: We examined protein expression of VDR in tumor tissue among 841 patients with prostate cancer in relation to risk of lethal prostate cancer within two prospective cohorts, the Physicians' Health Study and Health Professionals Follow-Up Study. We also examined the association of VDR expression with prediagnostic circulating 25(OH)D and 1,25-dihydroxyvitamin D levels and with two VDR single nucleotide polymorphisms, FokI and BsmI. RESULTS: Men whose tumors had high VDR expression had significantly lower prostate-specific antigen (PSA) at diagnosis (P for trend < .001), lower Gleason score (P for trend < .001), and less advanced tumor stage (P for trend < .001) and were more likely to have tumors harboring the TMPRSS2:ERG fusion (P for trend = .009). Compared with the lowest quartile, men whose tumors had the highest VDR expression had significantly reduced risk of lethal prostate cancer (hazard ratio [HR], 0.17; 95% CI, 0.07 to 0.41). This association was only slightly attenuated after adjustment for Gleason score and PSA at diagnosis (HR, 0.33; 95% CI, 0.13 to 0.83) or, additionally, for tumor stage (HR, 0.37; 95% CI, 0.14 to 0.94). Neither prediagnostic plasma vitamin D levels nor VDR polymorphisms were associated with VDR expression. CONCLUSION: High VDR expression in prostate tumors is associated with a reduced risk of lethal cancer, suggesting a role of the vitamin D pathway in prostate cancer progression.
PURPOSE: Data suggest that circulating 25-hydroxyvitamin D [25(OH)D] interacts with the vitamin D receptor (VDR) to decrease proliferation and increase apoptosis for some malignancies, although evidence for prostate cancer is less clear. How VDR expression in tumor tissue may influence prostate cancer progression has not been evaluated in large studies. PATIENTS AND METHODS: We examined protein expression of VDR in tumor tissue among 841 patients with prostate cancer in relation to risk of lethal prostate cancer within two prospective cohorts, the Physicians' Health Study and Health Professionals Follow-Up Study. We also examined the association of VDR expression with prediagnostic circulating 25(OH)D and 1,25-dihydroxyvitamin D levels and with two VDR single nucleotide polymorphisms, FokI and BsmI. RESULTS:Men whose tumors had high VDR expression had significantly lower prostate-specific antigen (PSA) at diagnosis (P for trend < .001), lower Gleason score (P for trend < .001), and less advanced tumor stage (P for trend < .001) and were more likely to have tumors harboring the TMPRSS2:ERG fusion (P for trend = .009). Compared with the lowest quartile, men whose tumors had the highest VDR expression had significantly reduced risk of lethal prostate cancer (hazard ratio [HR], 0.17; 95% CI, 0.07 to 0.41). This association was only slightly attenuated after adjustment for Gleason score and PSA at diagnosis (HR, 0.33; 95% CI, 0.13 to 0.83) or, additionally, for tumor stage (HR, 0.37; 95% CI, 0.14 to 0.94). Neither prediagnostic plasma vitamin D levels nor VDR polymorphisms were associated with VDR expression. CONCLUSION: High VDR expression in prostate tumors is associated with a reduced risk of lethal cancer, suggesting a role of the vitamin D pathway in prostate cancer progression.
Authors: E M Colin; A E Weel; A G Uitterlinden; C J Buurman; J C Birkenhäger; H A Pols; J P van Leeuwen Journal: Clin Endocrinol (Oxf) Date: 2000-02 Impact factor: 3.478
Authors: N A Morrison; J C Qi; A Tokita; P J Kelly; L Crofts; T V Nguyen; P N Sambrook; J A Eisman Journal: Nature Date: 1994-01-20 Impact factor: 49.962
Authors: Rohit Mehra; Scott A Tomlins; Jianjun Yu; Xuhong Cao; Lei Wang; Anjana Menon; Mark A Rubin; Kenneth J Pienta; Rajal B Shah; Arul M Chinnaiyan Journal: Cancer Res Date: 2008-05-15 Impact factor: 12.701
Authors: G Attard; J Clark; L Ambroisine; G Fisher; G Kovacs; P Flohr; D Berney; C S Foster; A Fletcher; W L Gerald; H Moller; V Reuter; J S De Bono; P Scardino; J Cuzick; C S Cooper Journal: Oncogene Date: 2007-07-16 Impact factor: 9.867
Authors: Julie L Kasperzyk; William V Shappley; Stacey A Kenfield; Lorelei A Mucci; Tobias Kurth; Jing Ma; Meir J Stampfer; Martin G Sanda Journal: J Urol Date: 2011-09-23 Impact factor: 7.450
Authors: Gary Hardiman; Stephen J Savage; E Starr Hazard; Robert C Wilson; Sean M Courtney; Michael T Smith; Bruce W Hollis; Chanita Hughes Halbert; Sebastiano Gattoni-Celli Journal: Pharmacogenomics Date: 2016-06-30 Impact factor: 2.533
Authors: Yaw A Nyame; Adam B Murphy; Diana K Bowen; Gregory Jordan; Ken Batai; Michael Dixon; Courtney M P Hollowell; Stephanie Kielb; Joshua J Meeks; Peter H Gann; Virgilia Macias; Andre Kajdacsy-Balla; William J Catalona; Rick Kittles Journal: J Clin Oncol Date: 2016-02-22 Impact factor: 44.544
Authors: Jamila Al-Azhri; Yali Zhang; Wiam Bshara; Gary Zirpoli; Susan E McCann; Thaer Khoury; Carl D Morrison; Stephen B Edge; Christine B Ambrosone; Song Yao Journal: Clin Cancer Res Date: 2016-07-12 Impact factor: 12.531
Authors: Emmanuel Y Jingwi; Muneer Abbas; Luisel Ricks-Santi; Danyelle Winchester; Desta Beyene; Agnes Day; Tammey J Naab; Olakunle O Kassim; Georgia M Dunston; Robert L Copeland; Yasmine M Kanaan Journal: Anticancer Res Date: 2015-03 Impact factor: 2.480
Authors: Travis A Gerke; Neil E Martin; Zhihu Ding; Elizabeth J Nuttall; Edward C Stack; Edward Giovannucci; Rosina T Lis; Meir J Stampfer; Phillip W Kantoff; Giovanni Parmigiani; Massimo Loda; Lorelei A Mucci Journal: Prostate Date: 2015-09-07 Impact factor: 4.104